Piramal Pharma Solutions unveils payload-linker suite
Analysis based on 14 articles · First reported May 13, 2026 · Last updated May 13, 2026
The unveiling of the new payload-linker suite by Piramal Enterprises — Piramal Pharma Solutions is expected to positively impact the pharmaceutical and biotechnology markets by accelerating the development and delivery of complex therapies like ADCs. This expansion, part of a larger $90 million investment by Piramal Group, reinforces U.S.-based manufacturing capabilities, potentially improving supply chain security and efficiency for innovator companies.
Piramal Enterprises — Piramal Pharma Solutions, a subsidiary of Piramal Group, officially unveiled a new, state-of-the-art payload-linker development and manufacturing suite at its Riverview, United States — Michigan drug substance facility on May 13, 2026. This launch is a key part of Piramal Enterprises — Piramal Pharma Solutions' broader $90 million investment plan to expand U.S.-based manufacturing capabilities, which also includes enhancements to its sterile injectables facility in Lexington, United States — Kentucky. The new suite, equipped with advanced containment, automation, and analytical technologies, is designed to accelerate partners' timelines and meet the increasing demand for antibody-drug conjugates (ADCs) and other bioconjugate therapies. Peter DeYoung, CEO of Piramal Global Pharma, emphasized the investment's commitment to U.S.-based innovation and manufacturing. The Riverview facility, with over 60 years of experience, is a dedicated payload-linker supplier for Piramal Enterprises — Piramal Pharma Solutions' ADCelerate™ platform.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard